PRL-secreting PitNET accounts for approximately 40% of all pituitary tumors; the resulting hyperprolactinemia may cause infertility, galactorrhea, neurological dysfunction due to mass effect or it may remain asymptomatic.62 Most patients with PRL-secreting PitNETs achieve biochemical control and radiographic tumor regression with pharmacologic treatment (dopamine agonists); TSR represents the next best option for patients intolerant or unresponsive to medical treatment, while RT is reserved for resistant or malignant tumors.62 This evidence concerns the gene PRL and neoplasm.